Didric Cederholm Portfolio
Invests via Lion Point Capital LP | Managed by Didric Cederholm, Jim Freeman
Invests via Lion Point Capital LP
Managed by Didric Cederholm, Jim Freeman
Automatically Tracked
Active in Nordic venture circles, Didric Cederholm is an angel investor and operator who blends hands-on product and growth experience with early-stage capital deployment. He invests primarily into SaaS, fintech and developer tooling companies across Northern Europe, writing direct checks and leading small syndicates while providing go-to-market support. His background includes founding and scaling startups, early-team product leadership, and board-advisory roles that help translate technical roadmaps into commercial traction. Capital partners and founders cite his operational involvement as a catalyst for Series A readiness, and he sources deals through operator networks and founder referrals. Investment scope centers on pre-seed to Series A rounds with an emphasis on founder-led technical teams and measurable ARR or user-growth signals.
Active in Nordic venture circles, Didric Cederholm is an angel investor and operator who blends hands-on product and growth experience with early-stage capital deployment. He invests primarily into SaaS, fintech and developer tooling companies across Northern Europe, writing direct checks and leading small syndicates while providing go-to-market support. His background includes founding and scaling startups, early-team product leadership, and board-advisory roles that help translate technical roadmaps into commercial traction. Capital partners and founders cite his operational involvement as a catalyst for Series A readiness, and he sources deals through operator networks and founder referrals. Investment scope centers on pre-seed to Series A rounds with an emphasis on founder-led technical teams and measurable ARR or user-growth signals.
Investment Philosophy & Strategy
Operator-led angel strategy focused on pre-seed to Series A SaaS, fintech and developer tooling in Northern Europe. Prioritises founder-led technical teams with measurable ARR or user-growth signals, deploying concentrated checks and leading small syndicates. Emphasises capital efficiency and milestone-driven follow-ons, pairing go-to-market and product growth support to accelerate Series A readiness. Underwrites opportunities through operator networks and referrals, prefers pragmatic risk management via hands-on board/advisory involvement and clear commercial traction metrics.
Operator-led angel strategy focused on pre-seed to Series A SaaS, fintech and developer tooling in Northern Europe. Prioritises founder-led technical teams with measurable ARR or user-growth signals, deploying concentrated checks and leading small syndicates. Emphasises capital efficiency and milestone-driven follow-ons, pairing go-to-market and product growth support to accelerate Series A readiness. Underwrites opportunities through operator networks and referrals, prefers pragmatic risk management via hands-on board/advisory involvement and clear commercial traction metrics.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
17.88%
Gain -2.42%
Monthly
0.67%
Yearly
8.35%
Drawdown
42.32%
$15.82M
Equity
Holdings
$15.82M
Investment
$19.33M
$304.38M
Profit -$570,010.67
Realized
$307.9M
Unrealized
-$3.52M
Dividends
$21.07M
Goals
Avg. 11% completed goals
Yearly
Gain > 9% 2026
Yearly
Loss < 33% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-2.42%
Profit
-$570,010.67
Win %
38%
This Week
Compared To Last Week
Gain
-8.77%
Profit
-$1.52M
Win %
38%
This Month
Compared to last month
Gain
-11.19%
Profit
-$1.99M
Win %
38%
This Year
Compared to last year
Gain
-22.07%
Profit
-$4.48M
Win %
41%
RPRX Royalty Pharma plc
+2.2%
+$28,034 
VTRS Viatris Inc.
+1.43%
+$7,202 
PCRX Pacira BioSciences Inc.
+0.04%
+$202.5 
MIST Milestone Pharmaceuticals Inc.
-9.12%
-$59,450 
CUE Cue Biopharma, Inc.
-8.98%
-$88,781.43 
JSPR Jasper Therapeutics Inc.
-7.93%
-$19,623 
AZTA Azenta, Inc.
-7.2%
-$25,511 
CMPS Compass Pathways plc Depositary Receipt
-7.19%
-$66,800 
MLTX MoonLake Immunotherapeutics
-6.53%
-$45,225 
DYN Dyne Therapeutics Inc.
-6.28%
-$17,280 
RCKT Rocket Pharmaceuticals Inc.
-6.14%
-$12,470 
MLYS Mineralys Therapeutics, Inc.
-5.59%
-$12,705 
SNDX Syndax Pharmaceuticals Inc.
-4.91%
-$24,120 
KURA Kura Oncology Inc.
-4.9%
-$21,850 
ARDX Ardelyx Inc.
-4.74%
-$19,940.75 
BHVN Biohaven Ltd.
-4.42%
-$26,108.5 
SRPT Sarepta Therapeutics Inc.
-3.91%
-$19,807.5 
GERN Geron Corporation
-3.66%
-$26,010 
SPRB Spruce Biosciences Inc.
-3.52%
-$1,460 
JANX Janux Therapeutics Inc.
-3.49%
-$11,495 
BNTC Benitec Biopharma Inc.
-3.31%
-$17,360 
FENC Fennec Pharmaceuticals Inc.
-3.2%
-$37,204.41 
GHRS GH Research plc
-3.19%
-$6,120 
EWTX Edgewise Therapeutics, Inc.
-2.68%
-$9,327.5 
RGNX Regenxbio Inc.
-2.65%
-$5,054 
QURE uniQure N.V.
-2.02%
-$6,688.5 
MCRB Seres Therapeutics, Inc.
-1.98%
-$1,578.5 
ARQT Arcutis Biotherapeutics Inc.
-1.72%
-$2,625 
IPHA Innate Pharma S.A. Sponsored ADR
-1.35%
-$1,623.02 
PRAX Praxis Precision Medicines Inc.
-1.07%
-$11,792.54 
BBIO BridgeBio Pharma, Inc.
-0.9%
-$3,025 
HUMA Humacyte, Inc.
-0.7%
-$2,015 
INVA Innoviva Inc.
-0.69%
-$1,189 
LNTH Lantheus Holdings, Inc.
-0.08%
-$440 
IRON Disc Medicine Inc.
-0.02%
-$81 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 497 | Longs Won 260/497 52% | Profit Factor 1.77 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $5.97M |
| Average Win $2.69M | Best Trade (Dec 31) $64.29M | Sharpe Ratio -60.3 |
| Average Loss -$1.66M | Worst Trade (Sep 29) -$37.03M | Z-Score -5.8 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 2w | Expectancy $612,443.11 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 36.91% | 49.82% | 59.38% | 67.26% | 74.08% | 80.16% | 85.69% | 90.79% | 95.54% |
| Consecutive Losing Trades | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx Inc. | 128,650 | $366,652.5 | $400,744.75 | - | $34,092.25 | 9.3% | -4.74% |
| ARQT Arcutis Biotherapeutics Inc. | 5,250 | $73,132.5 | $150,150 | - | $77,017.5 | 105.31% | -1.718% |
| AZTA Azenta, Inc. | 9,700 | $322,622 | $328,733 | - | $6,111 | 1.89% | -7.202% |
| BBIO BridgeBio Pharma, Inc. | 5,000 | $126,650 | $332,625 | - | $205,975 | 162.63% | -0.901% |
| BHVN Biohaven Ltd. | 51,700 | $1.46M | $564,822.5 | - | -$896,906.5 | -61.36% | -4.418% |
| BNTC Benitec Biopharma Inc. | 62,000 | $648,900 | $507,160 | - | -$141,740 | -21.84% | -3.31% |
| CMPS Compass Pathways plc Depositary Receipt | 80,000 | $454,000 | $862,800 | - | $408,800 | 90.04% | -7.186% |
| CUE Cue Biopharma, Inc. | 52,928 | $1.35M | $899,384.33 | - | -$452,396.79 | -33.47% | -8.984% |
| DYN Dyne Therapeutics Inc. | 18,000 | $352,080 | $257,940 | - | -$94,140 | -26.74% | -6.279% |
| EWTX Edgewise Therapeutics, Inc. | 9,100 | $225,817 | $338,292.5 | - | $112,475.5 | 49.81% | -2.683% |
| FENC Fennec Pharmaceuticals Inc. | 112,434 | $957,842.22 | $1.13M | - | $168,645.27 | 17.61% | -3.197% |
| GERN Geron Corporation | 578,000 | $1.78M | $684,930 | - | -$1.1M | -61.55% | -3.659% |
| GHRS GH Research plc | 10,200 | $129,540 | $185,742 | - | $56,202 | 43.39% | -3.19% |
| HUMA Humacyte, Inc. | 650,000 | $633,421.25 | $283,660 | - | -$349,761.25 | -55.22% | -0.705% |
| INVA Innoviva Inc. | 8,200 | $163,918 | $169,863 | - | $5,945 | 3.63% | -0.695% |
| IPHA Innate Pharma S.A. Sponsored ADR | 81,151 | $142,014 | $118,480.46 | - | -$23,533.54 | -16.57% | -1.351% |
| IRON Disc Medicine Inc. | 8,100 | $439,388 | $458,784 | - | $19,396 | 4.41% | -0.018% |
| JANX Janux Therapeutics Inc. | 19,000 | $262,200 | $317,585 | - | $55,385 | 21.12% | -3.493% |
| JSPR Jasper Therapeutics Inc. | 465,000 | $2.15M | $227,803.5 | - | -$1.93M | -89.42% | -7.931% |
| KURA Kura Oncology Inc. | 46,000 | $407,100 | $424,350 | - | $17,250 | 4.24% | -4.897% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Didric Cederholm?
The largest contributions to the portfolio's profits come from the following stocks: Canadian Solar Inc - $137.19M, Lattice Semiconductor Corporation - $123.67M, Marvell Technology, Inc - $37.33M, ORIG - $34.21M, and Ally Financial Inc - $31.74M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Comscore Inc - $44.75M, BurgerFi International Inc - $37.03M, PDC Energy Inc - $35.42M, CPE - $35.12M, and Carrizo Oil & Gas Inc - $29.94M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Didric Cederholm's portfolio generate?
The portfolio generates substantial dividend income, with a total of $21.07M earned over time. The largest contributors to dividend income include Chord Energy Corp - $6.63M, Ally Financial Inc - $2.94M, CenterPoint Energy Inc - $1.99M, Expand Energy Corporation - $1.79M, and Marvell Technology, Inc - $1.23M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Didric Cederholm's monthly returns?
Didric Cederholm's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Didric Cederholm's strategy be considered aggressive or moderate?
Didric Cederholm's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Didric Cederholm's strategy?
Didric Cederholm's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
